Cite
Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma.
MLA
Miyama, Yu, et al. “Lower Neutrophil‐to‐lymphocyte Ratio and Positive Programmed Cell Death Ligand‐1 Expression Are Favorable Prognostic Markers in Patients Treated with Pembrolizumab for Urothelial Carcinoma.” Cancer Medicine, vol. 11, no. 22, Nov. 2022, pp. 4236–45. EBSCOhost, https://doi.org/10.1002/cam4.4779.
APA
Miyama, Y., Kaneko, G., Nishimoto, K., & Yasuda, M. (2022). Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma. Cancer Medicine, 11(22), 4236–4245. https://doi.org/10.1002/cam4.4779
Chicago
Miyama, Yu, Go Kaneko, Koshiro Nishimoto, and Masanori Yasuda. 2022. “Lower Neutrophil‐to‐lymphocyte Ratio and Positive Programmed Cell Death Ligand‐1 Expression Are Favorable Prognostic Markers in Patients Treated with Pembrolizumab for Urothelial Carcinoma.” Cancer Medicine 11 (22): 4236–45. doi:10.1002/cam4.4779.